68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
Status:
Recruiting
Trial end date:
2024-02-04
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well 68Ga-PSMA PET/MRI or PET/CT works in early detection of
liver cancer. 68Gallium-PSMA is a radioactive tracer designed to circulate through the body
and attach itself to the prostate- specific membrane antigen (PSMA) protein on liver cancer
cells. Magnetic resonance imaging (MRI) is a scan that uses magnetic and radio waves to
produce detailed structural information of the organs, tissues, and structures within the
body. Positron emission tomography (PET) is an imaging test that helps to measure the
information about functions of tissues and organs within the body. A PET scan uses a
radioactive drug (tracer) to show this activity. Computed tomography (CT) scan uses X-rays to
create images of the bones and internal organs within your body. Combining a PET scan with an
MRI or CT scan may help make the images easier to interpret. This trial may help determine if
68Ga- PSMA PET/MRI or PET/CT can improve upon the diagnosis and management of liver cancer in
the future.